Dan Puckett Biography and Net Worth



Dan joined Shockwave Medical in April 2016 as the company’s Chief Financial Officer.  Most recently, Dan served as CFO for Counsyl, a venture-backed DNA testing and genetic counseling company.

From 2011 to 2015, Dan served as CFO for Ariosa Diagnostics, a molecular diagnostics company (acquired by Roche in 2015).  Dan came to Ariosa from Forest Laboratories where he served as Executive Director, Operations of Cerexa, a Forest Laboratories subsidiary. Prior to Cerexa, Dan held senior finance and operations positions at Affymetrix, Inc., AOL and BHP Billiton Ltd.

Dan earned his MBA from the University of San Francisco and a BA degree in Accounting from Washington State University.

What is Dan Puckett's net worth?

The estimated net worth of Dan Puckett is at least $9.03 million as of February 1st, 2024. Mr. Puckett owns 27,732 shares of Shockwave Medical stock worth more than $9,030,371 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Puckett may own. Learn More about Dan Puckett's net worth.

How do I contact Dan Puckett?

The corporate mailing address for Mr. Puckett and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Dan Puckett's contact information.

Has Dan Puckett been buying or selling shares of Shockwave Medical?

In the last ninety days, Dan Puckett has sold $782,562.56 in shares of Shockwave Medical stock. Most recently, Dan Puckett sold 3,406 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a transaction totalling $782,562.56. Following the completion of the sale, the chief financial officer now directly owns 27,732 shares of the company's stock, valued at $6,371,704.32. Learn More on Dan Puckett's trading history.

Who are Shockwave Medical's active insiders?

Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.

Are insiders buying or selling shares of Shockwave Medical?

In the last year, insiders at the sold shares 47 times. They sold a total of 221,744 shares worth more than $52,184,011.04. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.

Information on this page was last updated on 3/26/2024.

Dan Puckett Insider Trading History at Shockwave Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2024Sell3,406$229.76$782,562.5627,732View SEC Filing Icon  
12/8/2023Sell200$173.88$34,776.0028,784View SEC Filing Icon  
5/11/2023Sell2,050$291.95$598,497.5029,398View SEC Filing Icon  
4/19/2023Sell1,002$264.67$265,199.3431,658View SEC Filing Icon  
3/20/2023Sell1,100$200.74$220,814.0033,658View SEC Filing Icon  
2/21/2023Sell1,100$192.84$212,124.0041,158View SEC Filing Icon  
2/2/2023Sell2,073$190.25$394,388.2541,158View SEC Filing Icon  
1/20/2023Sell1,100$177.45$195,195.0039,938View SEC Filing Icon  
12/20/2022Sell1,100$212.93$234,223.0039,938View SEC Filing Icon  
11/21/2022Sell1,100$246.96$271,656.0039,938View SEC Filing Icon  
10/20/2022Sell1,100$268.35$295,185.0039,938View SEC Filing Icon  
9/20/2022Sell1,100$291.33$320,463.0039,938View SEC Filing Icon  
8/22/2022Sell1,100$292.21$321,431.0039,938View SEC Filing Icon  
7/20/2022Sell1,350$207.09$279,571.5039,938View SEC Filing Icon  
6/21/2022Sell1,350$161.40$217,890.0039,938View SEC Filing Icon  
5/20/2022Sell1,350$161.38$217,863.0041,048View SEC Filing Icon  
4/19/2022Sell3,691$200.59$740,377.6939,938View SEC Filing Icon  
2/22/2022Sell6,621$144.71$958,124.91View SEC Filing Icon  
1/20/2022Sell1,500$146.49$219,735.00View SEC Filing Icon  
12/20/2021Sell2,700$168.73$455,571.00View SEC Filing Icon  
11/1/2021Sell2,500$219.72$549,300.00View SEC Filing Icon  
10/1/2021Sell2,500$195.47$488,675.00View SEC Filing Icon  
9/1/2021Sell2,500$216.93$542,325.00View SEC Filing Icon  
8/2/2021Sell2,500$176.29$440,725.00View SEC Filing Icon  
7/1/2021Sell2,500$189.55$473,875.00View SEC Filing Icon  
6/1/2021Sell2,500$178.66$446,650.0046,129View SEC Filing Icon  
5/3/2021Sell2,500$158.22$395,550.0046,130View SEC Filing Icon  
4/21/2021Sell5,000$149.20$746,000.0050,788View SEC Filing Icon  
4/19/2021Sell1,391$137.28$190,956.4846,897View SEC Filing Icon  
4/16/2021Sell1,109$138.71$153,829.3946,897View SEC Filing Icon  
3/1/2021Sell2,000$122.91$245,820.0051,570View SEC Filing Icon  
2/1/2021Sell2,000$117.68$235,360.0037,649View SEC Filing Icon  
1/4/2021Sell2,000$102.35$204,700.0037,650View SEC Filing Icon  
12/1/2020Sell2,000$94.36$188,720.0037,649View SEC Filing Icon  
11/10/2020Sell10,000$84.75$847,500.0042,677View SEC Filing Icon  
11/2/2020Sell2,000$67.44$134,880.0037,650View SEC Filing Icon  
10/15/2020Sell12,000$74.30$891,600.0037,649View SEC Filing Icon  
8/24/2020Sell527$60.00$31,620.0037,835View SEC Filing Icon  
8/21/2020Sell3,866$60.02$232,037.3242,112View SEC Filing Icon  
8/4/2020Sell1,430$50.01$71,514.3045,878View SEC Filing Icon  
2/14/2020Sell50,000$44.25$2,212,500.0058,000View SEC Filing Icon  
9/9/2019Sell75,000$34.71$2,603,250.00
See Full Table

Dan Puckett Buying and Selling Activity at Shockwave Medical

This chart shows Dan Puckett's buying and selling at Shockwave Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shockwave Medical Company Overview

Shockwave Medical logo
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $325.63
Low: $322.61
High: $331.58

50 Day Range

MA: $254.81
Low: $217.19
High: $325.63

2 Week Range

Now: $325.63
Low: $157.00
High: $331.58

Volume

814,172 shs

Average Volume

698,070 shs

Market Capitalization

$12.18 billion

P/E Ratio

84.14

Dividend Yield

N/A

Beta

0.9